Ranolazine: Focusing on angina pectoris

Drugs of Today

Volumn 42, Issue 3, 2006, Pages 177-183

  McCullough, Peter A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMLODIPINE; ARGININE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; ESTROGEN; IVABRADINE; NICORANDIL; NITRATE; NITRIC ACID DERIVATIVE; OXFENICINE; PIPERAZINE DERIVATIVE; RANOLAZINE; SILDENAFIL; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TADALAFIL; TESTOSTERONE; TRIMETAZIDINE; VARDENAFIL;

ACUTE CORONARY SYNDROME; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; COUNTERPULSATION; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MECHANISM; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HEADACHE; HEART ELECTROPHYSIOLOGY; HUMAN; LIVER TOXICITY; NEPHROTOXICITY; REVASCULARIZATION; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; STABLE ANGINA PECTORIS; STANDING; SUSTAINED DRUG RELEASE; UNSPECIFIED SIDE EFFECT;

ANGINA PECTORIS; ENZYME INHIBITORS; HUMANS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS;

EID: 33646245185     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.3.953590     Document Type: Review

References (22)

1. McCullough, P.A. Chronic angina: New medical options for treatment. Rev Cardiovasc Med 2005, 6: 152-61.
2. Abrams, J. Clinical practice. Chronic stable angina. N Engl J Med 2005, 352: 2524-33.
3. Yang, E.H., Barsness, G.W., Gersh, B.J., Chandrasekaran, K., Lerman, A. Current and future treatment strategies for refractory angina. Mayo Clin Proc 2004, 79: 1284-92.
4. Gibbons, R.J., Abrams, J., Chatterjee, K. et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol 2003, 41: 159-68.
5. McCullough, P.A., Franklin, B.A. Atherosclerosis: Conventional risk factors and cardiac events - debunking an old myth about prevalence. Rev Cardiovasc Med 2004, 5: 185-6.
6. Hansson, G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352: 1685-95.
7. McCullough, P.A., Silver, M.A., Kennard, E.D., Kelsey, S.F., Michaels, A.D.; IEPR Investigators. Impact of body mass index on outcomes of enhanced counterpulsation therapy. Am Heart J 2006, 151: 139.
8. Bonetti, P.O., Holmes, D.R. Jr., Lerman, A., Barsness, G.W. Enhanced external counterpulsation for ischemic heart disease: What's behind the curtain? J Am Coll Cardiol 2003, 41: 1918-25.
9. Folmes, C.D., Clanachan, A.S., Lopaschuk, G.D. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr Atheroscler Rep 2005, 7: 63-70.
10. Anderson, J.R., Khou, S., Nawarskas, J.J. Ranolazine: A potential new treatment for chronic stable angina. Heart Dis 2001, 3: 263-9.
11. Chazov, E.I., Lepakchin, V.K., Zharova, E.A. et al. Trimetazidine in Angina Combination Therapy - The TACT study: Trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005, 12: 35-42.
12. Koylan, N., Bilge, A.K., Adalet, K., Mercanoglu, F., Buyukozturk, K.; TTS Group. Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish Trimetazidine Study (TTS). Acta Cardiol. 2004, 59: 644-50.
13. Sellier, P., Broustet, J.P. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: A multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs 2003, 3: 361-9.
14. Manchanda, S.C. Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine. Int J Cardiol 2003, 88: 83-9.
15. Marzilli, M., Klein, W.W. Efficacy and tolerability of trimetazidine in stable angina: A meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis 2003, 14: 171-179.
16. Antzelevitch, C., Belardinelli, L., Wu L. et al. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther 2004, 9 (Suppl. 1): S65-83.
17. Rousseau, M.F., Pouleur, H., Cocco, G., Wolff, A.A. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005, 95: 311-6.
18. Chaitman, B.R., Skettino, S.L., Parker, J.O. et al.; MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004, 43: 1375-82.
19. Chaitman, B.R., Pepine, C.J., Parker, J.O. et al.; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 2004, 291: 309-16.
20. Pepine, C.J., Wolff, A.A. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 1999, 84: 46-50.
21. Thadani, U., Ezekowitz, M., Fenney, L., Chiang, Y.K. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group. Circulation 1994, 90: 726-34.
22. Cocco, G., Rousseau, M.F., Bouvy, T. et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 1992, 20: 131-8.